Cancer
Pancreatic cancer
胰腺癌
Tumours or cancer of the pancreas. Most are malignant; some arise from the hormone-producing islet cells.
Definition adapted from MeSH (US National Library of Medicine)
- hospitals in mainland China
- 192
- cities
- 59
with a paper from 2016–2025 or a registered study
where those hospitals are
Mainland China accounts for 27% of the world's English-language research papers on pancreatic cancer, 2021–2025 (19% in 2016–2020), and 17% of the world's registered trials on it have a site in China.
Research activity in public records, not a rating of care and not medical advice. How the numbers are made
192 hospitals in 59 cities
Order: papers led on pancreatic cancer, 2021–2025, then A–Z. Research activity, not a rating of care.
A hospital is listed when it led at least 6 papers or 1 trial on pancreatic cancer, or was a site in 4 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions
Cities with the most listed hospitals
Each opens pancreatic cancer in that city. 49 more cities are in the menu below.
- 227 papers led
- 212 papers led
- 163 papers led
- 115 papers led
- 114 papers led
- 103 papers led
- 91 papers led
- 88 papers led
- 77 papers led
- 71 papers led
- 71 papers led
- 70 papers led
- 66 papers led
- 66 papers led
- 63 papers led
- 60 papers ledNo open trial led
- 55 papers led
- 54 papers led
- 53 papers led
- 52 papers led
- 47 papers ledNo open trial led
- 46 papers ledNo open trial led
- 46 papers ledNo open trial led
- 45 papers led
- 44 papers led
- 44 papers ledNo open trial led
- 41 papers ledNo open trial led
- 39 papers ledNo open trial led
- 39 papers led
- 37 papers ledNo open trial led
- 37 papers ledNo open trial led
- 35 papers led
- 34 papers led
- 34 papers ledNo open trial led
- 32 papers ledNo open trial led
- 32 papers ledNo open trial led
- 30 papers ledNo open trial led
- 29 papers ledNo open trial led
- 29 papers ledNo open trial led
- 29 papers ledNo open trial led
- 28 papers ledNo open trial led
- 28 papers ledNo open trial led
- 28 papers led
- 27 papers ledNo open trial led
- 27 papers ledNo open trial led
- 26 papers led
- 25 papers ledNo open trial led
- 23 papers ledNo open trial led
- 23 papers led
- 23 papers ledNo open trial led
- 23 papers led
- 22 papers ledNo open trial led
- 22 papers led
- 22 papers ledNo open trial led
- 22 papers led
- 22 papers ledNo open trial led
- 21 papers ledNo open trial led
- 21 papers ledNo open trial led
- 21 papers ledNo open trial led
- 21 papers ledNo open trial led
- 20 papers ledNo open trial led
- 20 papers led
- 20 papers ledNo open trial led
- 20 papers ledNo open trial led
- 19 papers led
- 19 papers ledNo open trial led
- 18 papers ledNo open trial led
- 18 papers ledNo open trial led
- 17 papers ledNo open trial led
- 16 papers ledNo open trial led
- 16 papers led
- 16 papers ledNo open trial led
- 15 papers ledNo open trial led
- 15 papers ledNo open trial led
- 15 papers ledNo open trial led
- 14 papers ledNo open trial led
- 14 papers ledNo open trial led
- 14 papers ledNo open trial led
- 14 papers ledNo open trial led
- 13 papers ledNo open trial led
- 13 papers ledNo open trial led
- 12 papers ledNo open trial led
- 12 papers ledNo open trial led
- 12 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers led
- 11 papers led
- 11 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers ledNo open trial led
- 10 papers ledNo open trial led
- 10 papers ledNo open trial led
- 10 papers ledNo open trial led
- 10 papers ledNo open trial led
- 10 papers ledNo open trial led
- 10 papers ledNo open trial led
- 10 papers ledNo open trial led
- 10 papers ledNo open trial led
- 10 papers ledNo open trial led
- 10 papers ledNo open trial led
- 10 papers ledNo open trial led
- 10 papers led
- 9 papers ledNo open trial led
- 9 papers ledNo open trial led
- 9 papers ledNo open trial led
- 9 papers ledNo open trial led
- 9 papers led
- 9 papers led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers led
- 6 papers led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers led
- 3 papers ledNo open trial led
- 3 papers led
- 3 papers ledNo open trial led
- 3 papers led
- 3 papers ledNo open trial led
- 2 papers led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers led
- 2 papers ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers ledNo open trial led
No listed hospital matches these filters.
By university or health system 58
Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.
- 347 papers led6 hospitals
- 309 papers led6 hospitals
- 307 papers led6 hospitals
- 243 papers led6 hospitals
- 173 papers led4 hospitals
- 160 papers led6 hospitals
- 154 papers led6 hospitals
- 144 papers led4 hospitals
- 112 papers led5 hospitals
- 112 papers led4 hospitals
- 100 papers led6 hospitals
- 98 papers led6 hospitals
- 97 papers led6 hospitals
- 85 papers led4 hospitals
- 80 papers led4 hospitals
- 74 papers led6 hospitals
- 72 papers led6 hospitals
- 72 papers led6 hospitals
- 71 papers led1 hospital
- 71 papers led6 hospitals
- 68 papers led5 hospitals
- 66 papers led6 hospitals
- 64 papers led5 hospitals
- 63 papers led6 hospitals
- 62 papers led5 hospitals
- 56 papers led3 hospitals
- 54 papers led3 hospitals
- 50 papers led3 hospitals
- 50 papers led5 hospitals
- 42 papers led4 hospitals
- 42 papers led6 hospitals
- 41 papers led6 hospitals
- 41 papers led1 hospital
- 38 papers led6 hospitals
- 36 papers led4 hospitals
- 34 papers led5 hospitals
- 30 papers led6 hospitals
- 28 papers led1 hospital
- 27 papers led3 hospitals
- 26 papers led4 hospitals
- 26 papers led3 hospitals
- 25 papers led3 hospitals
- 24 papers led5 hospitals
- 23 papers led1 hospital
- 23 papers led3 hospitals
- 23 papers led1 hospital
- 21 papers led4 hospitals
- 21 papers led6 hospitals
- 19 papers led6 hospitals
- 18 papers led3 hospitals
- 16 papers led4 hospitals
- 15 papers led1 hospital
- 12 papers led1 hospital
- 10 papers led1 hospital
- 8 papers led2 hospitals
- 6 papers led1 hospital
- 6 papers led2 hospitals
- 2 papers led1 hospital
open trials on pancreatic cancer in China
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with at least one listed hospital as lead sponsor or site. 196 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.
Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial
What the phases mean (US National Cancer Institute)
- RecruitingHRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07240766
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingHRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07296341
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingKRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07353645
Age 18 years to 75 years (registered criteria)
Led by Nanjing Drum Tower HospitalNanjing
- RecruitingNano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic Cancer
- Phase
- N/A
- Started
- 2026-06
- Posted
- Registry
- NCT07408505
Age 18 years to 75 years (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- RecruitingA Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
- Phase
- Phase 3
- Started
- 2026-02
- Posted
- Registry
- NCT07409272
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai
- RecruitingExploratory Clinical Study of Claudin18.2-Targeted Activated DC and CAR-T Therapy in Advanced Pancreatic Cancer.
- Phase
- Early phase 1
- Started
- 2026-02
- Posted
- Registry
- NCT07416240
Age 18 years to 80 years (registered criteria)
Led by Hainan Cancer HospitalHaikou
- RecruitingCAR-NK Cells (CL-NK-003) in Pancreatic Cancer
- Phase
- Phase 1
- Started
- 2026-02
- Posted
- Registry
- NCT07425483
Age 18 years to 75 years (registered criteria)
Led by Changhai HospitalShanghai
- RecruitingStudy of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07435038
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou
- RecruitingSurufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07436741
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingA Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07438106
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingAI-Powered Precision Decision-Making for Pancreatic Diseases
- Phase
- Not given
- Started
- 2026-03
- Posted
- Registry
- NCT07439757
Age 18 years to 80 years (registered criteria)
Led by Changhai HospitalShanghai
- RecruitingIBI343 in Combination Therapy for Advanced Malignant Solid Tumors
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07483554
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou
- RecruitingTo Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for Treating Pancreatic Cancer With Peritoneal Involvement.
- Phase
- N/A
- Started
- 2026-03
- Posted
- Registry
- NCT07493421
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingHepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07504471
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingAssociation Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer
- Phase
- Not given
- Started
- 2026-05
- Posted
- Registry
- NCT07529626
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan University; 2 listed hospitals as study sitesChangsha, Shanghai, Xi'an
- RecruitingSub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors
- Phase
- Not given
- Started
- 2026-04
- Posted
- Registry
- NCT07552467
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- Recruiting18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
- Phase
- N/A
- Started
- 2026-04
- Posted
- Registry
- NCT07557225
Age 18 years to Not stated (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingStudy of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2026-03
- Posted
- Registry
- NCT07589205
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingAn Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07589569
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Tianjin
- RecruitingNALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07595172
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
- Phase
- Phase 1/Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07610798
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingRadiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery
- Phase
- Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07632118
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingStudy of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations
- Phase
- Phase 1/Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07640295
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Harbin, Nanjing, Shanghai, Taiyuan, Wuhan, Zhengzhou
- RecruitingA Study of Dose Escalation of ES502 in Patients With Advanced Pancreatic Cancer
- Phase
- Early phase 1
- Started
- 2026-05
- Posted
- Registry
- NCT07649928
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingSpatial Multi-omics and Intelligent Early Warning of Pancreatic Cancer Cachexia
- Phase
- Not given
- Started
- 2026-04
- Posted
- Registry
- NCT07670286
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingA Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation
- Phase
- Phase 1/Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07678593
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Shanghai, Shenyang, Wuhan, Xi'an, Zhengzhou
- RecruitingSBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07683221
Age 18 years to 75 years (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- RecruitingPatient-Derived Organoid-on-a-Chip Model for Personalized Prediction of Chemotherapy Efficacy in Pancreatic Cancer
- Phase
- Not given
- Started
- 2026-02
- Posted
- Registry
- NCT07683845
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic Cancer
- Phase
- Early phase 1
- Started
- 2026-06
- Posted
- Registry
- NCT07707531
Age 18 years to Not stated (registered criteria)
Led by Huashan HospitalShanghai
- Recruiting68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
- Phase
- N/A
- Started
- 2026-08
- Posted
- Registry
- NCT07760012
Age 18 years to Not stated (registered criteria)
Led by Peking University Third HospitalBeijing
- RecruitingYMN-136 Vaccine for Patients With Advanced Hepatobiliary and Pancreatic Malignancies
- Phase
- Phase 1
- Started
- 2026-08
- Posted
- Registry
- NCT07763301
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingA Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07784374
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingIRE After Chemotherapy for Locally Advanced Pancreatic Cancer
- Phase
- N/A
- Started
- 2026-05
- Posted
- Registry
- NCT07799935
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingGnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Metastatic PDAC
- Phase
- Phase 1/Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07802184
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingAn Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07806058
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingBecotatug Vedotin Plus Anti-PD-1 and S-1 in Patients With EGFR-Positive Advanced Pancreatic Cancer Who Have Failed at Least One Line of Standard Therapy
- Phase
- N/A
- Started
- 2026-10
- Posted
- Registry
- NCT07892573
Age 18 years to 85 years (registered criteria)
Led by Ningbo Medical Center Lihuili HospitalNingbo
- RecruitingLiver Metastasis in Pancreatic Ductal Adenocarcinoma: Regulatory Mechanisms and Clinical Significance
- Phase
- Not given
- Started
- 2026-10
- Posted
- Registry
- NCT07933952
Age 18 years to 80 years (registered criteria)
Led by Second Affiliated Hospital of Nanjing Medical UniversityNanjing
- RecruitingNectin-4 Specific LMW PET Probe Imaging in Multiple Solid Tumors
- Phase
- N/A
- Started
- 2025-05
- Posted
- Registry
- NCT05321316
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingPancreatic Cancer and Diabetes Mellitus
- Phase
- Not given
- Started
- 2025-01
- Posted
- Registry
- NCT06585072
Age 18 years to Not stated (registered criteria)
Led by Changzheng HospitalShanghai
- RecruitingPolymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer
- Phase
- Phase 3
- Started
- 2025-02
- Posted
- Registry
- NCT06752811
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai
- RecruitingA Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06758544
Age 18 years to 75 years (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingIBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06770439
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingHRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06770452
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingAlbumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06789679
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingCAR-NK Cells (CL-NK-001) in Pancreatic Cancer
- Phase
- Phase 1
- Started
- 2025-04
- Posted
- Registry
- NCT06816823
Age 18 years to 70 years (registered criteria)
Led by Changhai HospitalShanghai
- RecruitingClinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06821503
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Harbin, Nanchang, Nanjing, Shanghai, Shenyang, Tianjin, Xi'an, Zhengzhou
- RecruitingA Study of GC203 TIL in PDCA (RJ)
- Phase
- Early phase 1
- Started
- 2025-02
- Posted
- Registry
- NCT06828328
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingClinical Study of Carbon Ion Radiotherapy for Pancreatic Cancer.
- Phase
- N/A
- Started
- 2025-03
- Posted
- Registry
- NCT06840067
Age 18 years to 80 years (registered criteria)
Led by Gansu Wuwei Tumor HospitalWuwei
- RecruitingAdapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)
- Phase
- Phase 1/Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06844422
Age 18 years to 75 years (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- RecruitingThe Purpose of This Study is to Evaluate the Safety, Tolerability and Efficacy of TMT101 Injection Monotherapy in Patients With Advanced Pancreatic Cancer or Non-small Cell Lung Cancer(NSCLC)
- Phase
- Phase 1
- Started
- 2025-03
- Posted
- Registry
- NCT06861543
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingStudy of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06895031
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation
- Phase
- Phase 1
- Started
- 2025-03
- Posted
- Registry
- NCT06898385
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Recruiting18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis
- Phase
- Not given
- Started
- 2025-04
- Posted
- Registry
- NCT06937112
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingAn Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT06938282
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingA Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06944106
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingThe Safety and Effectiveness of Hyperthermic Intraperitoneal Chemotherapy Combined With Intravenous Chemotherapy for Peritoneal Metastatic Pancreatic Cancer, a Phase II Clinical Trial
- Phase
- Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06946901
Age 18 years to 80 years (registered criteria)
Led by Zhongshan Hospital, Fudan University; 1 listed hospital as study siteChangsha, Shanghai
- RecruitingQL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06951997
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingA Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT06953999
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesHangzhou, Harbin, Shanghai
- RecruitingA Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)
- Phase
- Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06962267
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingAdjuvant Pancreatic Therapy Guided by MRD
- Phase
- N/A
- Started
- 2025-06
- Posted
- Registry
- NCT06966440
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingA Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
- Phase
- Phase 2/Phase 3
- Started
- 2025-10
- Posted
- Registry
- NCT06989437
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Lanzhou, Shanghai, Taiyuan, Wenzhou, Xi'an, Zhengzhou
- RecruitingRecombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT07006077
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou
- RecruitingThe Characteristics of Oral Microbiota in Chronic Pancreatitis and Autoimmune Pancreatitis
- Phase
- Not given
- Started
- 2025-02
- Posted
- Registry
- NCT07015580
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingConstruction and Clinical Application of the Immune Map of Pancreatic Cancer Evolution
- Phase
- Not given
- Started
- 2025-05
- Posted
- Registry
- NCT07034339
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT07040228
Age 18 years to 80 years (registered criteria)
Led by Cancer Hospital CAMS – ShenzhenShenzhen
- RecruitingA Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT07066098
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-07
- Posted
- Registry
- NCT07066657
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Harbin, Shanghai, Wuhan, Zhengzhou
- RecruitingA Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT07079228
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer
- Phase
- Not given
- Started
- 2025-05
- Posted
- Registry
- NCT07080021
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingA Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-08
- Posted
- Registry
- NCT07090499
Age 18 years to Not stated (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingA Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT07101679
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingA Study of GV20-0251 in Advanced or Refractory Solid Tumors
- Phase
- Phase 1
- Started
- 2025-09
- Posted
- Registry
- NCT07106827
Age 18 years to Not stated (registered criteria)
Led by West China HospitalChengdu
- RecruitingQL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07110064
Age 18 years to Not stated (registered criteria)
Led by Nanjing Drum Tower HospitalNanjing
- RecruitingA Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07114315
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Tianjin
- RecruitingArtificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer
- Phase
- Not given
- Started
- 2025-08
- Posted
- Registry
- NCT07117045
Age 50 years to Not stated (registered criteria)
Led by Changhai HospitalShanghai
- RecruitingHRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07131514
Age 18 years to 80 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingPGHD-AI Intelligent Model for the Nutritional Assessment and Intervention of Patients After Radical Surgery for Pancreatic Cancer.
- Phase
- N/A
- Started
- 2025-07
- Posted
- Registry
- NCT07167264
Age 18 years to 80 years (registered criteria)
Led by Shanghai General HospitalShanghai
- RecruitingStereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07173387
Age 18 years to 75 years (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- RecruitingA Single-Arm Investigator-Initiated Tria (IIT) Evaluating the Safety and Preliminary Efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in Patients With Unresectable Pancreatic Cancer
- Phase
- Early phase 1
- Started
- 2025-07
- Posted
- Registry
- NCT07198659
Age 18 years to 70 years (registered criteria)
Led by Xijing HospitalXi'an
- RecruitingHRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer
- Phase
- Phase 3
- Started
- 2025-11
- Posted
- Registry
- NCT07232875
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingFirstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer
- Phase
- Phase 3
- Started
- 2025-11
- Posted
- Registry
- NCT07235930
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingIrinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07238283
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07255404
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Kunming, Nanchang, Shanghai, Shenyang, Wuhan, Zhengzhou
- RecruitingPhase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07262567
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingClinical Application of PET Imaging Targeting CLDN18.2 in Malignant Tumors
- Phase
- Not given
- Started
- 2025-09
- Posted
- Registry
- NCT07301814
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- RecruitingIRE Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07306273
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingCryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07306286
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingLDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07312422
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Provincial People's HospitalHangzhou
- RecruitingA Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With Pain
- Phase
- Not given
- Started
- 2025-12
- Posted
- Registry
- NCT07326137
Age not stated (registered criteria)
Led by Tongji HospitalWuhan
- Recruiting68Ga-PFA2 PET Imaging for the Diagnosis of Annexin A2-Positive Tumors
- Phase
- Not given
- Started
- 2025-06
- Posted
- Registry
- NCT07331532
Age 18 years to 80 years (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingLaryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia
- Phase
- Not given
- Started
- 2025-11
- Posted
- Registry
- NCT07359586
Age not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingLiposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors:A Prospective Exploratory Study
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT07542002
Age 18 years to 75 years (registered criteria)
Led by Ningbo Medical Center Lihuili HospitalNingbo
- RecruitingA Study on a Predictive Model for Efficacy and Prognosis of Pancreatic Carcinoma Based on Multimodal Data
- Phase
- Not given
- Started
- 2025-12
- Posted
- Registry
- NCT07561814
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingRomiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07586813
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingTo Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
- Phase
- Phase 1
- Started
- 2025-08
- Posted
- Registry
- NCT07594964
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing
- RecruitingA IIT Study of 177Lu-DOTA-SNA040
- Phase
- Early phase 1
- Started
- 2025-11
- Posted
- Registry
- NCT07595237
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingPreliminary Trial of SNA014 for Pancreatic Cancer
- Phase
- Early phase 1
- Started
- 2025-10
- Posted
- Registry
- NCT07597772
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingEfficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Maintenance Therapy Compared to Maintenance Therapy Alone in Advanced Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07600268
Age 18 years to 70 years (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- RecruitingIBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT07692750
Age 18 years to Not stated (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingStudy of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT07823049
Age not stated (registered criteria)
Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Yangzhou, Yinchuan, Zhengzhou
- RecruitingNKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor
- Phase
- Phase 1
- Started
- 2024-11
- Posted
- Registry
- NCT06134960
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Phase
- Phase 2
- Started
- 2024-02
- Posted
- Registry
- NCT06172478
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Guangzhou
- RecruitingGPC3/Mesothelin-CAR-γδT Cells Against Cancers
- Phase
- Phase 1
- Started
- 2024-05
- Posted
- Registry
- NCT06196294
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingEvaluation of diagnostiC Capacity of eccDNAs as Biomarkers in Indetermined biLiary Stricture(ECCBILE)
- Phase
- Not given
- Started
- 2024-03
- Posted
- Registry
- NCT06277531
Age 18 years to 85 years (registered criteria)
Led by Peking University Third Hospital; 1 listed hospital as study siteBeijing
- RecruitingSafety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC) and Advanced Pancreatic Cancer With Lymph Node Metastases
- Phase
- Phase 1
- Started
- 2024-01
- Posted
- Registry
- NCT06278454
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChongqing, Shanghai, Suzhou, Tianjin, Zhengzhou
- RecruitingStudy of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer
- Phase
- Early phase 1
- Started
- 2024-04
- Posted
- Registry
- NCT06326736
Age 18 years to 75 years (registered criteria)
Led by Jinling HospitalNanjing
- RecruitingNeoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer
- Phase
- Phase 1
- Started
- 2024-04
- Posted
- Registry
- NCT06344156
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingXH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer
- Phase
- N/A
- Started
- 2024-03
- Posted
- Registry
- NCT06353646
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingPD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients
- Phase
- Phase 2
- Started
- 2024-06
- Posted
- Registry
- NCT06359275
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06361888
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Suzhou, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingTreatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients
- Phase
- Not given
- Started
- 2024-04
- Posted
- Registry
- NCT06375473
Age 18 years to 100 years (registered criteria)
Led by Peking Union Medical College Hospital; 7 listed hospitals as study sitesBeijing, Hefei, Nanning, Ningbo, Shanghai, Wuhan, Zhengzhou
- RecruitingA Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2024-04
- Posted
- Registry
- NCT06403735
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHarbin, Kunming, Nanchang, Shanghai
- RecruitingExploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2024-06
- Posted
- Registry
- NCT06427239
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingAdjuvant Chemoradiotherapy Versus Chemotherapy for Pancreatic Cancer (ADJUPANC)
- Phase
- Phase 3
- Started
- 2024-08
- Posted
- Registry
- NCT06427447
Age 18 years to 75 years (registered criteria)
Led by Changhai HospitalShanghai
- RecruitingCentral-boost Ablative Radiation Therapy for Solid Tumors (CBART)
- Phase
- Phase 2
- Started
- 2024-05
- Posted
- Registry
- NCT06427460
Age 18 years to 75 years (registered criteria)
Led by Changhai HospitalShanghai
- RecruitingA Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
- Phase
- Phase 1/Phase 2
- Started
- 2024-06
- Posted
- Registry
- NCT06428409
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Shanghai, Wuhan
- RecruitingHypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06435260
Age 18 years to 75 years (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingPhase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2024-06
- Posted
- Registry
- NCT06454448
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Phase
- Phase 1
- Started
- 2024-07
- Posted
- Registry
- NCT06465069
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Shanghai
- RecruitingEvaluate the Safety and Efficacy of BGT007H Cell Therapy in Patients With Relapsed/Refractory Pancreatic Cancer
- Phase
- N/A
- Started
- 2024-05
- Posted
- Registry
- NCT06478225
Age 18 years to 75 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingIvonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06491472
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- RecruitingNALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer
- Phase
- N/A
- Started
- 2024-04
- Posted
- Registry
- NCT06494514
Age 18 years to Not stated (registered criteria)
Led by Nanjing Drum Tower HospitalNanjing
- RecruitingClinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer
- Phase
- Early phase 1
- Started
- 2024-07
- Posted
- Registry
- NCT06496373
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingA Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
- Phase
- Phase 1
- Started
- 2024-07
- Posted
- Registry
- NCT06500052
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingClinical Study of Lewis Antigen Assay Combined With CA19-9 Assay to Assess Prognosis in Patients With Pancreatic Cancer
- Phase
- N/A
- Started
- 2024-08
- Posted
- Registry
- NCT06515587
Age 18 years to 75 years (registered criteria)
Led by Shanghai General HospitalShanghai
- RecruitingAdebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06531278
Age 18 years to 75 years (registered criteria)
Led by Shanghai General HospitalShanghai
- RecruitingCadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2024-09
- Posted
- Registry
- NCT06532617
Age 18 years to 80 years (registered criteria)
Led by Shanghai General HospitalShanghai
- RecruitingMilaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06534762
Age 18 years to 65 years (registered criteria)
Led by Zhejiang Provincial People's HospitalHangzhou
- RecruitingA New Strategy for Preoperative Drainage of Resectable Pancreatic Head Cancer Combined Severe Obstructive Jaundice
- Phase
- N/A
- Started
- 2024-08
- Posted
- Registry
- NCT06541340
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingExploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06547736
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingBortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06572813
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingStudy of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors
- Phase
- Early phase 1
- Started
- 2024-09
- Posted
- Registry
- NCT06577532
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingIrinotecan Liposome in Combination With Capecitabine
- Phase
- N/A
- Started
- 2024-08
- Posted
- Registry
- NCT06578052
Age 18 years to 80 years (registered criteria)
Led by Cancer Hospital CAMS – ShenzhenShenzhen
- RecruitingAdebrelimab and Chidamide for Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2024-09
- Posted
- Registry
- NCT06584227
Age 18 years to 75 years (registered criteria)
Led by Jinling HospitalNanjing
- RecruitingHRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06587061
Age 18 years to 80 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingSafety and Efficacy of BA1302 in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2024-09
- Posted
- Registry
- NCT06596915
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingThe Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer.
- Phase
- Not given
- Started
- 2024-09
- Posted
- Registry
- NCT06601010
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingImmunoPET Imaging of Pancreatic Cancer
- Phase
- N/A
- Started
- 2024-11
- Posted
- Registry
- NCT06602037
Age 18 years to 70 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingAI-Assisted Non-Contrast CT for Multi-Cancer Screening
- Phase
- N/A
- Started
- 2024-10
- Posted
- Registry
- NCT06632886
Age 18 years to Not stated (registered criteria)
Led by Changhai HospitalShanghai
- RecruitingAI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort
- Phase
- Not given
- Started
- 2024-08
- Posted
- Registry
- NCT06638866
Age 18 years to Not stated (registered criteria)
Led by Changhai Hospital; 1 listed hospital as study siteJiaxing, Shanghai
- RecruitingNal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients
- Phase
- Phase 2
- Started
- 2024-03
- Posted
- Registry
- NCT06662006
Age 18 years to 75 years (registered criteria)
Led by Nanjing Drum Tower HospitalNanjing
- RecruitingTarget-specific immunoPET Imaging of Digestive System Carcinoma
- Phase
- N/A
- Started
- 2024-12
- Posted
- Registry
- NCT06715839
Age 18 years to 75 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingStudy of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06722911
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Provincial People's HospitalHangzhou
- RecruitingA Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer
- Phase
- Phase 1
- Started
- 2024-12
- Posted
- Registry
- NCT06760364
Age 18 years to 70 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingmFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06761027
Age 18 years to 75 years (registered criteria)
Led by Fujian Provincial Hospital; 1 listed hospital as study siteFuzhou
- RecruitingClinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms
- Phase
- Phase 2
- Started
- 2024-03
- Posted
- Registry
- NCT06767813
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesNanjing, Shanghai, Suzhou, Wenzhou, Zhengzhou
- RecruitingLiposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV
- Phase
- Phase 1/Phase 2
- Started
- 2024-06
- Posted
- Registry
- NCT06782685
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingStudy of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors
- Phase
- Phase 1
- Started
- 2024-07
- Posted
- Registry
- NCT06821048
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingClinical Application of PET Imaging Targeting MSLN in Malignant Tumors
- Phase
- Not given
- Started
- 2024-10
- Posted
- Registry
- NCT06843629
Age 18 years to 65 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingA Study of JMT203 in Patients With Cancer Cachexia
- Phase
- Phase 1/Phase 2
- Started
- 2024-05
- Posted
- Registry
- NCT06868849
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou
- RecruitingCDH17 CAR-T Therapy in Advanced Malignant Solid Tumors
- Phase
- Early phase 1
- Started
- 2024-12
- Posted
- Registry
- NCT06937567
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingBile Omics for Diagnosing Indeterminate Biliary Strictures
- Phase
- Not given
- Started
- 2024-01
- Posted
- Registry
- NCT07007832
Age 18 years to 90 years (registered criteria)
Led by Shanghai General HospitalShanghai
- RecruitingCtDNA-guided Maintenance Therapy in Pancreatic Cancer
- Phase
- Not given
- Started
- 2024-11
- Posted
- Registry
- NCT07054879
Age 18 years to Not stated (registered criteria)
Led by Nanjing Drum Tower HospitalNanjing
- RecruitingCarbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
- Phase
- Phase 1/Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT07433283
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Haikou, Harbin, Shanghai, Zhengzhou
- RecruitingArtificial Intelligence-Assisted 4D Dynamic Long-Axial PET Imaging for the Detection of Early Pancreatic Cancer Lesions
- Phase
- Not given
- Started
- 2024-11
- Posted
- Registry
- NCT07925125
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingConstruction of Molecular Diagnostic Marker Model for Pancreatic Cystic Tumors Based on Pancreatic Cystic Fluid Samples
- Phase
- Not given
- Started
- 2023-03
- Posted
- Registry
- NCT05737953
Age 18 years to Not stated (registered criteria)
Led by Changhai HospitalShanghai
- RecruitingMesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers
- Phase
- Phase 1
- Started
- 2023-03
- Posted
- Registry
- NCT05779917
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingThe Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced Pancreatic Cancer
- Phase
- N/A
- Started
- 2023-02
- Posted
- Registry
- NCT05802394
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingThe Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer
- Phase
- N/A
- Started
- 2023-02
- Posted
- Registry
- NCT05802407
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingPlasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors
- Phase
- Not given
- Started
- 2023-02
- Posted
- Registry
- NCT05847855
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer Center; 1 listed hospital as study siteChengdu, Shanghai
- RecruitingA Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2023-05
- Posted
- Registry
- NCT05859750
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Jinan, Shanghai, Wuhan
- RecruitingImplantation of iodine125-Seeds Combined With Chemotherapy in the Treatment of Metastatic Pancreatic Carcinoma
- Phase
- N/A
- Started
- 2023-08
- Posted
- Registry
- NCT05869474
Age 18 years to 80 years (registered criteria)
Led by Changhai HospitalShanghai
- RecruitingA Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer
- Phase
- Phase 1
- Started
- 2023-07
- Posted
- Registry
- NCT05911217
Age 18 years to 79 years (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Shanghai, Wuhan, Xi'an, Zhengzhou
- RecruitingPersonalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer
- Phase
- Early phase 1
- Started
- 2023-04
- Posted
- Registry
- NCT05916261
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingLRAMPS Versus LDP in Selected Early-stage Left-sided Pancreatic Cancer
- Phase
- N/A
- Started
- 2023-10
- Posted
- Registry
- NCT05939063
Age 18 years to 80 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT05969171
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
- Phase
- Phase 2
- Started
- 2023-10
- Posted
- Registry
- NCT06008288
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Zhengzhou
- RecruitingA Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
- Phase
- Phase 1
- Started
- 2023-08
- Posted
- Registry
- NCT06043466
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou
- RecruitingSintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2023-08
- Posted
- Registry
- NCT06050317
Age 18 years to 75 years (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- RecruitingA Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2023-10
- Posted
- Registry
- NCT06111274
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChengdu, Harbin, Shanghai, Wuhan
- RecruitingClinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes(CAR-T) for CEA Positive Advanced Malignant Solid Tumors
- Phase
- Phase 1
- Started
- 2023-11
- Posted
- Registry
- NCT06126406
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhu
- RecruitingA Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2023-11
- Posted
- Registry
- NCT06131840
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai
- RecruitingEarly-stage Detection of LIver, Biliary TRAct and PancReatic Cancers
- Phase
- Not given
- Started
- 2023-11
- Posted
- Registry
- NCT06139042
Age 40 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingEnucleation of Pancreatic Tumor by Blocking Abdominal Trunk and Superior Mesenteric Artery
- Phase
- N/A
- Started
- 2023-03
- Posted
- Registry
- NCT06164769
Age 14 years to 70 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Prospective Study of Liquid Biopsy for Pancreatic Cancer Early Detection
- Phase
- Not given
- Started
- 2023-12
- Posted
- Registry
- NCT06166147
Age 40 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesShanghai
- RecruitingClinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
- Phase
- Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT06199895
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingClinical Study of Multimodal Ablation Remodeling Immunosensitized PD-1 in the Treatment of Pancreatic Cancer With Liver Metastasis
- Phase
- N/A
- Started
- 2023-10
- Posted
- Registry
- NCT06307080
Age 18 years to 70 years (registered criteria)
Led by Shanghai General HospitalShanghai
- RecruitingA Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2023-04
- Posted
- Registry
- NCT06508307
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou
- RecruitingStudy of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
- Phase
- Phase 1/Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT06799637
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Kunming, Luoyang, Shanghai, Wuhan
- RecruitingA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2022-10
- Posted
- Registry
- NCT05208762
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai
- RecruitingPhase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
- Phase
- Phase 1/Phase 2
- Started
- 2022-04
- Posted
- Registry
- NCT05288205
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Harbin, Hefei, Jinan, Shanghai, Shenyang, Shenzhen, Wuhan, Xiamen, Zhengzhou
- RecruitingA Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
- Phase
- Phase 1
- Started
- 2022-06
- Posted
- Registry
- NCT05365581
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Hangzhou, Shanghai, Wuhan, Zhengzhou
- RecruitingAblative Carbon Ion Radiotherapy With Pencil Beam Scanning for Locally Advanced Unresectable Pancreatic Cancer
- Phase
- N/A
- Started
- 2022-07
- Posted
- Registry
- NCT05424159
Age 18 years to 80 years (registered criteria)
Led by Shanghai Proton and Heavy Ion CenterShanghai
- RecruitingTreatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T
- Phase
- N/A
- Started
- 2022-10
- Posted
- Registry
- NCT05620732
Age 18 years to 75 years (registered criteria)
Led by Shenzhen University General HospitalShenzhen
- RecruitingClinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer
- Phase
- Phase 3
- Started
- 2022-12
- Posted
- Registry
- NCT05653453
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesHarbin, Shanghai
- RecruitingRaman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
- Phase
- Not given
- Started
- 2022-09
- Posted
- Registry
- NCT06822413
Age not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang University; 3 listed hospitals as study sitesHangzhou, Nanchang, Shanghai
- RecruitingMSCAN: ctDNA Methylation as Prognostic and Theranostic Tool for Pancreatic Cancer
- Phase
- Not given
- Started
- 2022-10
- Posted
- Registry
- NCT07045571
Age not stated (registered criteria)
Led by Renji HospitalShanghai
- RecruitingMutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2021-10
- Posted
- Registry
- NCT04146298
Age 18 years to 75 years (registered criteria)
Led by Changhai HospitalShanghai
- RecruitingStudy of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2021-06
- Posted
- Registry
- NCT04900818
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Hefei, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou
- RecruitingAlbumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer
- Phase
- Phase 4
- Started
- 2021-03
- Posted
- Registry
- NCT05035147
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingA Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)
- Phase
- Early phase 1
- Started
- 2021-09
- Posted
- Registry
- NCT05098197
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingTriplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2021-11
- Posted
- Registry
- NCT05187338
Age 18 years to 70 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingSurufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2021-08
- Posted
- Registry
- NCT05218889
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingArtificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI)
- Phase
- Not given
- Started
- 2020-12
- Posted
- Registry
- NCT04743479
Age 50 years to 75 years (registered criteria)
Led by Changhai HospitalShanghai
- RecruitingMRE for Diagnosis of Pancreatic Masses
- Phase
- Not given
- Started
- 2020-10
- Posted
- Registry
- NCT06526442
Age 18 years to 80 years (registered criteria)
Led by Shengjing Hospital of China Medical UniversityShenyang
- RecruitingAssessment of the Prognosis of Pancreatic Cancer Patients Using 3D MRE
- Phase
- Not given
- Started
- 2020-10
- Posted
- Registry
- NCT06849063
Age 18 years to 80 years (registered criteria)
Led by Shengjing Hospital of China Medical UniversityShenyang
- RecruitingComparing Laparoscopic and Open Surgery for Pancreatic Carcinoma
- Phase
- N/A
- Started
- 2019-03
- Posted
- Registry
- NCT03785743
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingmFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients
- Phase
- Phase 2
- Started
- 2019-09
- Posted
- Registry
- NCT04084496
Age 18 years to 79 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingGemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2018-04
- Posted
- Registry
- NCT03498326
Age 18 years to 90 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingThe Comparision of Minimally-invasive and Open Pancreaticoduodenectomy for Pancreatic Cancer
- Phase
- N/A
- Started
- 2018-12
- Posted
- Registry
- NCT03747588
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingTrans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
- Phase
- Phase 2/Phase 3
- Started
- 2018-11
- Posted
- Registry
- NCT03755739
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- Not yet recruitingA Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer
- Phase
- Phase 3
- Started
- 2027-01
- Posted
- Registry
- NCT07138846
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingA Study of DCTY1102 Injection in Participants With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2026-05
- Posted
- Registry
- NCT07014878
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai
- Not yet recruitingJDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure
- Phase
- Phase 1/Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07175389
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingStudy on Efficacy and Safety of VMAT Technique With Local Dose Escalation for Unresectable Pancreatic Cancer
- Phase
- Not given
- Started
- 2026-01
- Posted
- Registry
- NCT07242911
Age 18 years to 76 years (registered criteria)
Led by Chifeng Tumor HospitalChifeng
- Not yet recruitingA Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer
- Phase
- Phase 3
- Started
- 2026-02
- Posted
- Registry
- NCT07383922
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingClinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer
- Phase
- Early phase 1
- Started
- 2026-09
- Posted
- Registry
- NCT07394205
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Wenzhou Medical UniversityWenzhou
- Not yet recruitingIBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07415525
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingEUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases
- Phase
- Not given
- Started
- 2026-03
- Posted
- Registry
- NCT07448376
Age 18 years to 70 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingSurufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07469956
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingChimeric Antigen Receptor Macrophages Targeting c-MET for Advanced Stage of Pancreatic Cancer Patients
- Phase
- Phase 1
- Started
- 2026-05
- Posted
- Registry
- NCT07553793
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- Not yet recruitingNon-Invasive Detection of claudin18.2 in Pancreatic and Gastric/Gastroesophageal Junction Cancer by [68Ga]Ga-NODAGA-SNA014 PET Imaging
- Phase
- Not given
- Started
- 2026-04
- Posted
- Registry
- NCT07554742
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingA Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
- Phase
- Phase 1
- Started
- 2026-06
- Posted
- Registry
- NCT07583771
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingA Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07623642
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Harbin
- Not yet recruitingStudy of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors
- Phase
- Phase 1
- Started
- 2026-07
- Posted
- Registry
- NCT07624214
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou
- Not yet recruitingPeptide Nanovaccine (ONVAX-01) Plus Anti-PD-1 Antibody and Chemotherapy in Advanced Pancreatic Cancer
- Phase
- Phase 1
- Started
- 2026-06
- Posted
- Registry
- NCT07637786
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingHSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion
- Phase
- Phase 1
- Started
- 2026-07
- Posted
- Registry
- NCT07699757
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingSafety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07745790
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingBaduanjin for Quality of Life in Pancreatic Cancer Chemotherapy
- Phase
- N/A
- Started
- 2026-08
- Posted
- Registry
- NCT07791550
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingFive-Element Music Therapy for Psychological Distress in Pancreatic Cancer Chemotherapy
- Phase
- N/A
- Started
- 2026-08
- Posted
- Registry
- NCT07796906
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingRetlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07814859
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- Not yet recruitingProtein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07825753
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingAlbumin-bound Paclitaxel (Ⅱ)-Combined Regimens for Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07828756
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingSurufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07833241
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- Not yet recruitingIntestinal Low-Dose Radiotherapy Combined With Immune Checkpoint Inhibitors in Solid Tumors With Liver Metastases
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07875465
Age 18 years to Not stated (registered criteria)
Led by Hangzhou Cancer HospitalHangzhou
- Not yet recruitingPhase 1 Study of NW-301V TCR-T Cells in Advanced Solid Tumors With KRAS G12V Mutation
- Phase
- Phase 1
- Started
- 2026-10
- Posted
- Registry
- NCT07875920
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou
- Not yet recruitingHRS-4642 Combined With Antitumor Agents for the Treatment of Perioperative Pancreatic Cancer
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07900789
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shanghai
- Not yet recruitingA Study to Assess the Effect of Itraconazole on the Pharmacokinetics of HRS-4642 Following Intravenous Infusion in Healthy Participants
- Phase
- Phase 1
- Started
- 2026-11
- Posted
- Registry
- NCT07906691
Age 18 years to 45 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangsha
- Not yet recruitingA Multicenter, Prospective Single-arm Study of Multimodal Thermal Therapy Combined With Toripalimab and AG Chemotherapy in the Treatment of Advanced Pancreatic Cancer
- Phase
- N/A
- Started
- 2026-10
- Posted
- Registry
- NCT07928362
Age 18 years to 75 years (registered criteria)
Led by Ruijin Hospital; 4 listed hospitals as study sitesChengdu, Qingdao, Shanghai, Xi'an
- Not yet recruitingNeoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT05562297
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- Not yet recruitingAdebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT06177522
Age 18 years to 80 years (registered criteria)
Led by Jinling HospitalNanjing
- Not yet recruitingQL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06750861
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingValidation of Joint-AI in Diagnosing Pancreatic Solid Lesions
- Phase
- N/A
- Started
- 2025-01
- Posted
- Registry
- NCT06753318
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingMetronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06759090
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingMaintenance Chemotherapy With S-1 vs. Observation After Adjuvant Therapy for Resected Pancreatic Cancer With High Risk of Recurrence/Metastasis
- Phase
- Phase 4
- Started
- 2025-07
- Posted
- Registry
- NCT06779318
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingChemoradiotherapy in Elderly Patients with Locally Advanced Pancreatic Cancer (70+).
- Phase
- Not given
- Started
- 2025-02
- Posted
- Registry
- NCT06844773
Age 70 years to 85 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- Not yet recruitingA Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Advanced Pancreatic Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06866977
Age 18 years to Not stated (registered criteria)
Led by Xiangya HospitalChangsha
- Not yet recruitingPersonalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06888648
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingPersonalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06888674
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingA Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC
- Phase
- Phase 1
- Started
- 2025-07
- Posted
- Registry
- NCT06913218
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingAdebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06916975
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingEvaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for Postoperative MRD Surveillance of Pancreatic Cancer
- Phase
- Not given
- Started
- 2025-04
- Posted
- Registry
- NCT06941987
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- Not yet recruitingClinical Study on Fecal Microbiota Transplantation for Diarrhea After Total Pancreatectomy
- Phase
- N/A
- Started
- 2025-05
- Posted
- Registry
- NCT06960122
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruiting22G-Adapt vs 22G-Franseen Needle Biopsy in EUS-Guided Tissue Acquisition of Solid Lesions
- Phase
- N/A
- Started
- 2025-07
- Posted
- Registry
- NCT07012694
Age 18 years to 85 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingTherapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies
- Phase
- N/A
- Started
- 2025-06
- Posted
- Registry
- NCT07014254
Age 18 years to 80 years (registered criteria)
Led by Xijing HospitalXi'an
- Not yet recruitingA Real-world Study of Liposomal Irinotecan (Onivyde)-Based Therapy in Patients With Locally Advanced/Metastatic Pancreatic Cancer in China
- Phase
- Not given
- Started
- 2025-07
- Posted
- Registry
- NCT07026123
Age 18 years to Not stated (registered criteria)
Led by Renji HospitalShanghai
- Not yet recruitingXH001 (New Antigen Tumor Vaccine) Combined With Chemotherapy as Adjuvant Therapy in Pancreatic Cancer
- Phase
- N/A
- Started
- 2025-08
- Posted
- Registry
- NCT07114666
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- Not yet recruitingClinical Application of PET Imaging Targeting GPA33 in Malignant Tumors
- Phase
- N/A
- Started
- 2025-10
- Posted
- Registry
- NCT07172503
Age 18 years to 70 years (registered criteria)
Led by Union HospitalWuhan
- Not yet recruitingA Clinical Study Evaluating the Safety, Tolerability, Preliminary Efficacy and Immunogenicity of a Tumor Vaccine Injection Targeting Stressinducible Proteins MICA/B in Combination With the AG Regimen in Patients With Metastatic Pancreatic Cancer
- Phase
- Early phase 1
- Started
- 2025-11
- Posted
- Registry
- NCT07231094
Age 18 years to Not stated (registered criteria)
Led by Third Xiangya HospitalChangsha
- Not yet recruitingA Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07233850
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- Not yet recruitingNimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07277452
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingStudy of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino
- Phase
- Early phase 1
- Started
- 2024-01
- Posted
- Registry
- NCT06156267
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingSecond-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2024-01
- Posted
- Registry
- NCT06166589
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- Not yet recruitingHR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer
- Phase
- Phase 3
- Started
- 2024-02
- Posted
- Registry
- NCT06217042
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingComparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients
- Phase
- Phase 2
- Started
- 2024-02
- Posted
- Registry
- NCT06234072
Age 18 years to Not stated (registered criteria)
Led by Shenzhen University General HospitalShenzhen
- Not yet recruitingOncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC
- Phase
- Phase 1
- Started
- 2024-05
- Posted
- Registry
- NCT06346808
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingSurufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2024-06
- Posted
- Registry
- NCT06361030
Age 18 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- Not yet recruitingNewly Emerging Immunotherapy for Pancreatic Cancer Treatment
- Phase
- Phase 1/Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06370754
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingNimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06409429
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingEarly Diagnosis of Pancreatic Cancer Via Deciphering Multi-modal Immunological Signatures
- Phase
- Not given
- Started
- 2024-08
- Posted
- Registry
- NCT06495749
Age not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingResearch of the Application of Artificial Intelligence Model "PANDA"
- Phase
- N/A
- Started
- 2024-08
- Posted
- Registry
- NCT06528223
Age not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingSurufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06531291
Age 18 years to 75 years (registered criteria)
Led by Renji HospitalShanghai
- Not yet recruitingA PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
- Phase
- Phase 1
- Started
- 2024-11
- Posted
- Registry
- NCT06614751
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing
- Not yet recruitingTP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor
- Phase
- Early phase 1
- Started
- 2024-09
- Posted
- Registry
- NCT06619886
Age 18 years to 75 years (registered criteria)
Led by Shanghai General HospitalShanghai
- Not yet recruitingAnlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)
- Phase
- Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06621095
Age 18 years to 75 years (registered criteria)
Led by Renji HospitalShanghai
- Not yet recruitingCanagliflozin With Gemcitabine in Pancreatic Carcinoma
- Phase
- N/A
- Started
- 2023-10
- Posted
- Registry
- NCT05903703
Age 18 years to Not stated (registered criteria)
Led by Hangzhou First People's HospitalHangzhou
- Enrolling by invitationNimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07386704
Age 18 years to 80 years (registered criteria)
Led by Peking University First HospitalBeijing
- Enrolling by invitationModified vs Conventional Blumgart Anastomosis of LPD for the Effects of Pancreatic Fistula of Periampullary Carcinoma
- Phase
- N/A
- Started
- 2023-07
- Posted
- Registry
- NCT06076252
Age 18 years to 75 years (registered criteria)
Led by Affiliated Hospital of Guangdong Medical UniversityZhanjiang
- Enrolling by invitationThe Differences of Complications Between LPD(Laparoscopic Pancreaticoduodenectomy) and OPD(Open Pancreaticoduodenectomy)
- Phase
- Not given
- Started
- 2020-01
- Posted
- Registry
- NCT06685939
Age 19 years to Not stated (registered criteria)
Led by Huadong Hospital, Fudan UniversityShanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Additional research sources
Before contacting a hospital
The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.
- How to startTalk with the treating doctor, prepare the records hospitals ask for, then write to two or three hospitals.
- Questions to check before asking about a trialWhat the registered criteria usually ask about, and what to ask the study team.
- Common questionsInternational patients, costs, trials and visas.
Where these numbers come from
Papers
5,743 English-language PubMed papers on pancreatic cancer with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search
Trials
ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 18 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.